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Abstract
Background: Information on the underlying cause of death of cancer patients is of interest because it can be used
to estimate net survival. The population-based Geneva Cancer Registry is unique because registrars are able to
review the official cause of death. This study aims to describe the difference between the official and revised
cause-of-death variables and the impact on cancer survival estimates.
Methods: The recording process for each cause of death variable is summarised. We describe the differences
between the two cause-of-death variables for the 5,065 deceased patients out of the 10,534 women diagnosed
with breast cancer between 1970 and 2009. The Kappa statistic and logistic regression are applied to evaluate the
degree of concordance. The impact of discordance on cause-specific survival is examined using the Kaplan Meier
method.
Results: The overall agreement between the two variables was high. However, several subgroups presented a
lower concordance, suggesting differences in calendar time and less attention given to older patients and more
advanced diseases. Similarly, the impact of discordance on cause-specific survival was small on overall survival but
larger for several subgroups.
Conclusion: Estimation of cancer-specific survival could therefore be prone to bias when using the official cause of
death. Breast cancer is not the more lethal cancer and our results can certainly not be generalised to more lethal
tumours.
Keywords: Cause-specific survival, Cause-of-death, Cancer registry, Concordance
Background
Population-based cancer survival is widely used to evalu-
ate the impact of health care systems in disease manage-
ment. Net survival is the survival that would be observed
if the only possible cause of death were the cancer of
interest [1]. Net survival is especially relevant when the
cohort of interest become older since the risk of dying
from other causes than cancer increases. Net survival is
also very useful when comparing subgroups whose mor-
tality due to other causes could be different and therefore
lead to biased estimation of the survival contrast.
Two main data designs can be distinguished, the cause-
specific and the relative survival designs, according to the
availability of information on cause of death. Such infor-
mation is rarely available in routine, population-based data
and net survival is then commonly estimated within the
relative survival framework. However, when information
about the underlying cause of death is available, net sur-
vival can be estimated using the cause-specific approach,
in which only deaths from the cause of interest are consid-
ered as ‘failures’, while deaths from other causes are
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censored. High-quality information on the cause of death
is required for each individual patient. This information is
commonly available only in clinical trials or hospital
series, but the cause-specific approach is sometimes used
on population-based data from cancer registries, where
the underlying cause of death is derived from death certifi-
cates. The underlying cause of death is the “disease or in-
jury which initiated the train of morbid events leading
directly to death” or the “circumstances of the accident or
violence which produced the fatal injury”. It is codified in
The International Classification of Diseases (ICD), which
was designed to classify causes of death for statistical
tabulation and research. Despite these international rules
(developed over 100 years), comparability and accuracy is-
sues still arise. Different medical terminologies, inaccurate
completion of the death certificates, misinterpretation or
misapplication of the coding rules for selection of the
underlying cause of death can cause comparability prob-
lems between different geographical areas and/or different
periods of time. The validity and accuracy of the reported
underlying cause of death may also be incorrect if the cli-
nician’s certification does not accurately reflect the clinical
history of events leading to death.
Percy et al. were the first to report that misclassification
of the underlying cause of death could bias the mortality
trends and therefore the estimation of cancer-specific sur-
vival [2]. Many other studies, then, have highlighted the
issue of inaccuracy of the cause of death information ob-
tained from death certificates [3-9]. Some studies have
shown that the proportion of misclassification can be very
high [4,10]. However, one study has suggested that the
proportion of misclassification can be lower for screened
patients dying from breast cancer [11].
The validity of disease-specific survival is based on the
assumption that the underlying cause of death is accur-
ately determined. The Geneva Cancer Registry, which
collects all the death certificates of routinely recorded
deaths in the Geneva canton (Switzerland), also reviews
the cause of death of each registered cancer patient
using all the available clinical information relating to
the patient’s disease and treatment. This leads to a par-
ticular and unique situation in which a second, validated
variable defining the cause of death is generated. This
second variable is considered to be a more reliable
record of the patient’s cause of death and so will be ex-
pected to give rise to more accurate estimates of cause-
specific survival.
The purposes of this study are (a) to describe the
process of recording the cause of death in the Geneva
Cancer Registry, (b) to investigate how accurate the rou-
tinely recorded cause of death is compared to the vali-
dated cause of death derived from clerical review and (c)
to examine whether the process of validation leads to
differences in the estimates of cause-specific survival.
Methods
Data
The data used in this study were obtained from the
Geneva Cancer Registry. All women diagnosed with a breast
cancer between 1970 and 2009 and resident in Geneva
were included in the study.
The Geneva Cancer Registry collects information on
incident cancer cases from various sources, including
hospitals, laboratories and private clinics, all requested
to report new cancer cases. Trained registrars systemat-
ically extract information from the medical records and
conduct further investigations in the case of missing key
data. The variables of interest for this study were cause
of death as specified on the death certificate, revised
cause of death, age at diagnosis, age at death, year of
diagnosis, year of death, social class, stage of the tumour,
treatment, sector of care and place of death. The Geneva
Cancer Registry has general registry approval by the
Swiss Federal Commission of Experts for professional
secrecy in medical research (Commission d’experts pour
le secret professionnel en matière de recherche medical).
This approval permits cancer data collection and its use
for research purposes.
Coding of cause of death
The Geneva Cancer Registry is notified of all deaths oc-
curring in the Geneva canton through three different
processes.
First, when a patient dies in the canton of Geneva, a
death certificate is compulsorily completed by the clin-
ician certifying the death who reports the primary, sec-
ondary and concomitant causes of death. The Geneva
Cancer Registry receives photocopies of all these death
certificates through the Geneva Health Administration;
and links them to the incidence database. The causes of
death reported on the death certificates represent the
original causes of death.
Meanwhile, once a year, the Federal Office of Statistics
(Office Federal de la Statistique, OFS) which is a na-
tional publicly-funded organisation collecting death cer-
tificates and maintaining a mortality database for the
whole of Switzerland provides the Geneva Cancer Regis-
try with a mortality database for the Geneva canton.
This is also linked to the incidence database to complete
and/or validate the process described above. This leads to
the definition of the official cause of death as the under-
lying cause of death derived from death certificates.
Finally, the Geneva Cancer Registry is provided on an
annual basis with information on the vital status of the
Canton population by the Cantonal Office of the Popula-
tion (Office Cantonal de la Population, OCP). OCP is a
regional administration that monitors births, deaths, mi-
gration, residency and civil partnerships. Only informa-
tion about the vital status of a patient (deceased or not),
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or information on whether a person has migrated from
Geneva is provided to the Registry. Information on the
cause of death is not available within this database.
After all the records are merged, the Cancer Registry
registrars then go back to the patient’s charts and review
the cause of death according to all the documents avail-
able. These include death certificates, autopsy reports,
letter at death written by general practitioners and all
the patient’s medical notes. By this process the cause of
death variable, the revised cause of death, is obtained.
Sometimes, the Geneva Cancer Registry is able to ob-
tain information about the occurrence of a death and its
cause through the health system (essentially the public
health system) before information from death certifi-
cates, OFS or OCP. This is particularly so for public sec-
tor, where information about the patient’s follow-up is
easier to obtain than in the private sector, with which
communication is mainly based on mails and willingness
of the practitioners.
Some patients leave the canton of Geneva after their
diagnosis with cancer, but return and die in Geneva.
These individuals are recorded as dead in the OFS data-
base. However, since no additional information on their
disease was collected in the Geneva area, they are con-
sidered lost to follow up at the point of their departure
by the Geneva Cancer Registry.
Statistical methods
We first examined the agreement between the official
underlying cause of death and the reviewed underlying
cause of death. We then evaluated the impact of such
disagreement on the cause-specific survival estimates.
We used the Kappa statistic to compare concordance
between the two cause-of-death variables for all patients
who had died (N = 5,065). The Kappa statistic corrects
for agreement expected by chance alone. Its values
range from 0 to 1; 0 represents no agreement whereas 1
is perfect agreement. We stratified the analysis accord-
ing to age at diagnosis, age at death, period of diagnosis,
period of death, social class, stage, treatment received,
sector of care and place of death. Age at diagnosis and
age at death were coded into 5 categories (0–49, 50–59,
60–69, 70–79 and 80 and over), whilst four periods were
used for the temporal analysis of diagnosis and death
(1970–79, 1980–89, 1990–99, 2000–09). Social class
was based on the patient’s last job or, if missing, on the
patient’s partner’s job. It was divided in four categories
(high, medium, low and unknown) [12]. Stage followed
the TNM classification [13] with 5 subgroups (stage I,
stage II, stage III, stage IV, unknown). We distinguished
5 categories for the treatment each patient received: sur-
gery only, surgery plus adjuvant therapy, hormonal
treatment, others (including a mix of different palliative
therapies), and an absence of treatment. Only treatments
received during the first six months after diagnosis are re-
corded by the registry according to the IARC rules [14].
Sector of care was defined as private or public sector. We
also defined 5 categories of place of death: public hospital,
retirement home, private hospital, patient’s home and
unknown.
We used variance-weighted least-squares regression to
evaluate trends in the Kappa values for sub-groups [15].
Table 1 Baseline characteristics of the cohort of female
breast cancer patients diagnosed in Geneva between
1970 and 2009
Overall Deceased
N % N %
Age at diagnosis (mean, SD) 61,5 (0,14) 66,8 (0,21)
Age groups
0-50 2′422 23.0 749 14.8
50-59 2′469 23.4 831 16.4
60-69 2′383 22.6 1′055 20.8
70-79 1′949 18.5 1′317 26.0
80+ 1′311 12.5 1′113 22.0
Period of diagnosis
1970-79 1′890 17.9 1′576 31.1
1980-89 2′192 20.8 1′552 30.6
1990-99 2′896 27.5 1′302 25.7
2000-09 3′556 33.8 635 12.5
Socioeconomic status
High 1′620 15.4 597 11.8
Middle 5′092 48.3 2′171 42.9
Low 2′390 22.7 1′484 29.3
Unknown 1′432 13.6 813 16.1
Stage
I 3′434 32.6 1′014 20.0
II 4′355 41.3 2′044 40.4
III 1′219 11.6 807 15.9
IV 585 5.6 490 9.7
Unknown 941 8.9 710 14.0
Treatment
Surgery only 1′890 17.9 1′252 24.7
Surgery + adjuvant 7′340 69.7 2′693 53.2
No treatment 473 4.5 421 8.3
Hormones only 547 5.2 448 8.8
Others 284 2.7 251 5.0
Sector of care
Private 5′122 48.6 2′028 40.0
Public 5′412 51.4 3′037 60.0
Total 10′534 100.0 5′065 100.0
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We used logistic regression to evaluate the odds of
disagreement between the official and revised cause of
death, associated with each of the factors listed above.
We also examined the concordance between the offi-
cial and the revised cause of death as a function of time
since diagnosis: patients who died within five years after
diagnosis, patients who died after 5 years but before
10 years of follow-up and patients who died after 10 but
before 15 years of follow-up. Because of small numbers,
patients dying more than 15 years after their diagnosis
were not considered.
To estimate the impact of discordance upon cause-
specific survival, we derived Kaplan Meier cause-specific
survival curves for the whole cohort (N = 10,534) using
both official and revised cause of death. In cause-specific
survival analyses, patients are classified as presenting the
event if they are recorded as dying from their cancer
while those who die from other causes are censored at
the date of their death. We performed subgroup survival
analysis by age group, period of diagnosis, stage of the
disease and treatment.
Results
The cohort consisted of 10,534 women (mean age
61.5 years) diagnosed between 1970 and 2009. Nearly
half belonged to the middle social class groups (Table 1).
About three quarters of the women were diagnosed at
early stage of disease (stage I and II). Almost 90% under-
went surgery, associated with adjuvant treatments such
as radiotherapy (63%), hormones (44%) and chemother-
apy (33%; data not shown).
Among the 5,065 women who have died, the official
and the revised underlying cause of death were identical
for 4,620 patients (91%) (Table 2). 254 cases (5%) were
recorded as dying of breast cancer according to their
death certificate but as dying from other causes in the
revised data. Among these women, the cause of death
was mostly recoded to heart diseases (48%) and other
malignant tumours (20%). Conversely, 191 cases (3.8%)
were recorded as dying from other causes according to
their death certificate but as dying from breast cancer in
the revised data. Among these women, the main causes
of death reported on their original death certificates
were other malignant tumours (40%) or an imprecise
code (19%) (Table 2). The overall value of the kappa test
was 0.82 (p-value < 0.001).
Unadjusted concordance varied greatly between sub-
groups (Table 3). The concordance was significantly
lower with increasing age, from 0.87 for ages 0–49 to
0.74 for ages 80+ (p-value for trend test = 0.008). Similar
age-related trends, though not significant, were found
among the three subpopulations defined by time since
diagnosis. These age-related patterns were much less
marked for age at death. Concordance was comparable
in all four periods of diagnosis although it tended to be
lower in the earlier periods. Concordance was greater
for early stage of disease (stage I and II) compared to ad-
vanced stage (III and IV), from 0.84 for stage I to 0.63
for stage IV (p-value for trend <0.001). However, the
concordance between the two underlying causes of death
for women with missing stage (about 14%) tended to be
higher than those for stage IV (and stage III). If these re-
cords corresponded to advanced diseases, as it is often
the case, this stage-related pattern could be greatly at-
tenuated. This pattern was more marked for patients de-
ceased within the first five years after diagnosis. A clear
pattern was found according to the type of treatment
with higher concordance for complete, with curative
intent, treatment (0.83), intermediate concordance for
palliative treatment (0.73) and lower concordance for
non-treated patients (0.63). This pattern was mostly
found among patients who died within five years since
Table 2 Cause of death among women diagnosed with breast cancer in Geneva between 1970 and 2009: effect of
reclassification of the official underlying cause of death by the Geneva Cancer Registry
Cause of death 5′065
Concordant 4′620
Breast cancer 2′508
Other cause 2′112
Discordant 445
Distribution of discordant cases
Revised cause of death Breast cancer as the official cause of death Official cause of death Breast cancer as the revised cause of death
N % N %
Other tumour 50 19.7 Other tumour 77 40.3
Heart disease 121 47.6 Heart disease 35 18.3
Imprecise code 11 4.3 Imprecise code 37 19.4
Other 72 28.4 Other 42 22.0
254 100.0 191 100.0
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Table 3 Concordance by subgroups between the official underlying cause of death and the revised underlying cause
of death for women diagnosed with breast cancer in Geneva between 1970 and 2009
All data Between 0 and 4 years offollow-up
Between 5 and 9 years of
follow-up
Between 10 and 14 years of
follow-up
N % Kappa SD N % Kappa SD N % Kappa SD N % Kappa SD
Overall 5,065 100.0 0.82 0.01 2,497 100.0 0.76 0.02 1,275 100.0 0.86 0.03 626 100.0 0.83 0.04
Age at diagnosis
0-49 749 14.8 0.87 0.04 317 12.7 0.76 0.06 210 16.5 0.91 0.07 94 15.0 0.92 0.10
50-59 831 16.4 0.87 0.03 380 15.2 0.79 0.05 210 16.5 0.81 0.07 87 13.9 0.90 0.11
60-69 1,055 20.8 0.82 0.03 442 17.7 0.75 0.05 239 18.7 0.87 0.06 146 23.3 0.76 0.08
70-79 1,317 26.0 0.81 0.03 600 24.0 0.73 0.04 339 26.6 0.82 0.05 237 37.9 0.79 0.06
80+ 1,113 22.0 0.74 0.03 758 30.1 0.71 0.04 277 21.7 0.79 0.06 62 9.9 0.63 0.12
Trend test p = 0.008 p = 0.394 p = 0.222 p = 0.105
Age at death
0-49 353 7.0 0.80 0.05 248 9.9 0.76 0.06 94 7.4 0.92 0.10 8 1.3 N/A
50-59 593 11.7 0.86 0.04 350 14.0 0.80 0.05 160 12.6 0.88 0.08 64 10.2 0.96 0.12
60-69 813 16.1 0.79 0.04 427 17.1 0.73 0.05 222 17.4 0.83 0.07 87 13.9 0.86 0.11
70-79 1,105 21.8 0.81 0.03 580 23.2 0.73 0.04 270 21.2 0.85 0.06 130 20.8 0.86 0.09
80+ 2,201 43.5 0.77 0.02 892 35.7 0.72 0.03 529 41.5 0.81 0.04 337 53.8 0.73 0.05
Trend test p = 0.339 p = 0.405 p = 0.256 N/A
Period of diagnosis
1970-79 1,576 31.1 0.80 0.03 695 27.8 0.72 0.04 354 27.8 0.81 0.05 198 31.6 0.75 0.07
1980-89 1,552 30.6 0.80 0.03 686 27.5 0.69 0.04 387 30.5 0.84 0.05 206 32.9 0.82 0.07
1990-99 1,302 25.7 0.86 0.03 654 26.2 0.81 0.04 366 28.7 0.88 0.05 217 34.7 0.91 0.07
2000-09 635 12.5 0.84 0.04 462 18.5 0.81 0.05 168 13.2 0.90 0.07 5 0.8 N/A
Trend test p = 0.143 p = 0.036 p = 0.229 N/A
Social Class
High 597 11.8 0.81 0.04 281 11.3 0.76 0.06 144 11.3 0.86 0.08 77 12.3 0.77 0.11
Medium 2,171 42.9 0.85 0.02 1,034 41.4 0.78 0.03 553 43.3 0.89 0.04 290 46.3 0.86 0.06
Low 1,484 29.3 0.80 0.03 735 29.4 0.71 0.04 363 28.5 0.82 0.05 177 28.3 0.86 0.07
Unknown 813 16.1 0.79 0.04 447 17.9 0.76 0.05 215 16.9 0.85 0.07 82 13.1 0.73 0.11
Trend testˠ p = 0.569 p = 0.297 p = 0.492 p = 0.556
Stage
Stage I 1,014 20.0 0.84 0.03 280 11.2 0.78 0.06 305 23.9 0.85 0.06 198 31.6 0.84 0.07
Stage II 2,044 40.4 0.83 0.02 901 36.1 0.77 0.03 564 44.2 0.87 0.04 286 46.7 0.84 0.06
Stage III 807 15.9 0.77 0.04 538 21.6 0.74 0.04 175 13.7 0.80 0.08 58 9.3 0.76 0.13
Stage IV 490 9.7 0.63 0.04 427 17.1 0.55 0.05 50 3.9 0.95 0.14 8 1.3 0.38 0.28
Unknown 710 14.0 0.79 0.04 351 14.1 0.70 0.05 181 14.2 0.82 0.07 76 12.1 0.84 0.11
Trend testˠ p = 0.000 p = 0.000 p = 0.963 p = 0.272
Treatment
Surgery only 1,252 24.7 0.83 0.03 436 17.5 0.77 0.05 323 25.3 0.85 0.06 216 34.5 0.82 0.07
Surg + adj. 2,693 53.2 0.86 0.02 1,186 47.5 0.82 0.03 766 60.1 0.87 0.04 367 58.6 0.85 0.05
No treatment 421 8.3 0.63 0.05 317 12.7 0.61 0.06 69 5.4 0.79 0.12 23 3.7 0.47 0.21
Hormones 448 8.9 0.73 0.05 345 13.8 0.70 0.05 88 6.9 0.81 0.11 14 2.2 0.86 0.26
Others 251 5.0 0.65 0.06 213 8.5 0.60 0.07 29 2.3 0.87 0.18 6 1.0 0.57 0.37
Sector of care
Private 2,028 40.0 0.86 0.02 870 34.8 0.81 0.03 550 43.1 0.86 0.04 286 45.7 0.87 0.06
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diagnosis. We found no association between social class
and concordance, but a higher concordance for patients
who were monitored (0.86) or who have died (0.85) in
the private sector than for those in the public sector
(0.80 and 0.76, respectively).
Unadjusted odds ratios of disagreement between the
official and the revised underlying causes of death are
presented in Table 4 for the overall cohort and for the
three subcohorts defined by length of follow-up. The
odds of disagreement increased significantly with age at
diagnosis (as continuous variable) for all the patients
(OR 1.03, 95% CI [1.02; 1.03]) and for the three subco-
horts. We observed the same trend when using age at
death as continuous variable (OR 1.02, 95% CI [1.01;
1.02] for all patients). Period of diagnosis was not signifi-
cantly associated with disagreement but we did observe
a significant decreasing trend for period of death as a
continuous variable for all patients and the subcohorts
(OR: 0.97, 95% CI: [0.96-0.98] for all patients). We did
not find a significant trend for stage of the disease when
considering all patients or the subcohorts defined by
follow-up. Patients treated palliatively had significantly
higher odds of disagreement (OR: 2.50, 95% CI [1.82;
3.43] for non-treated, 1.76 95% CI [1.26; 2.46] for pa-
tients treated with hormones and 1.34, 95% CI [0.86;
2.1] for other palliative treatment). The same trend was
observed for the three subcohorts although not statisti-
cally significant. Patients treated in the public sector also
had a higher risk of disagreement (OR: 1.47, 95% CI
[1.20; 1.81] for all patients) as well as those who died in
a public hospital. We did not observe differences by so-
cial class. We were unable to perform a logistic regres-
sion for the subcohort defined by a follow-up time
between 10 and 15 years because of the small number of
observations (<10) for several variables.
Figure 1 presents the breast cause-specific survival
curves up to 20 years since diagnosis using the two differ-
ent cause-of-death variables, for all breast cancer patients
regardless their final vital status. The survival curves
matched almost perfectly, with a difference in 20-year sur-
vival lower than 1%. The estimation of proportion of pa-
tients alive after twenty years of follow-up when using the
official cause of death was 60.51%, 95% CI [59.11; 61.89]
and 61.26, 95% CI [59.85; 62.64] when using the revised
cause of death.
We compared cause-specific survival curves estimated
with the revised and official underlying cause of death for
selected subgroups (Figure 2). We estimated and pre-
sented results only if 10 women were remaining in the ex-
posed group and/or the difference between the two curves
was larger than 1%. Among patients aged 70–79 the sur-
vival at 20-year was 53.9% (95% CI [50.0; 57.6]) when
using the revised cause of death and 51.2% (95% CI [47.3;
54.9]) with the official cause of death. The 20-year survival
was greater when using the revised cause of death among
the two first period of diagnosis. 1.7% and 1.6% difference
for 1970–79 and 1980–89 respectively. We also observed
a difference for patients treated with surgery. The 20-year
survival was 65.2%, 95% CI [62.4; 68.0], based on the re-
vised cause of death and 63.0%, 95% CI [60.1; 65.8] when
using only death certificates.
A difference was already present at 10 years for several
subgroups. Among patients with no treatment, the esti-
mation was larger for reviewed cause of death with 3.5%
difference. Among patients with hormonal therapy, the
survival was 4.3% higher, 37.0%, 95% CI [29.5; 44.6] for
Table 3 Concordance by subgroups between the official underlying cause of death and the revised underlying cause
of death for women diagnosed with breast cancer in Geneva between 1970 and 2009 (Continued)
Public 3,037 60.0 0.80 0.02 1,627 65.2 0.73 0.02 725 56.9 0.86 0.04 340 54.3 0.79 0.05
Period of death
1970-79 630 12.4 0.70 0.04 548 21.9 0.71 0.04 82 6.4 0.67 0.11 - -
N/A
1980-89 1,196 23.6 0.74 0.03 658 26.4 0.68 0.04 362 28.4 0.84 0.05 149 23.8
1990-99 1,483 29.3 0.83 0.03 694 27.8 0.78 0.04 377 29.6 0.87 0.05 211 33.7
2000-09 1,756 34.7 0.88 0.02 597 23.9 0.84 0.05 454 35.6 0.88 0.05 266 42.5
Trend test p = 0.000 p = 0.007 p = 0.140 N/A
Place of death
Public hospital 2,845 56.2 0.76 0.02 1,573 63.0 0.69 0.03 677 53.1 0.82 0.04 315 50.3 0.78 0.06
Retirement
home
1,291 25.5 0.83 0.03 570 22.8 0.77 0.04 328 25.7 0.88 0.06 172 27.5 0.79 0.08
Private hospital 150 3.0 0.85 0.08 55 2.2 0.74 0.13 47 3.7 0.77 0.14 24 3.8 1.00 0.20
Home 374 7.4 0.91 0.05 143 5.7 0.94 0.08 113 8.9 0.87 0.09 54 8.3 0.90 0.14
Others 263 5.2 0.96 0.06 122 4.9 0.96 0.09 70 5.5 0.95 0.12 38 6.1 0.92 0.16
Missing 142 2.8 0.92 0.08 34 1.4 0.94 0.17 40 3.1 0.83 0.16 25 4.0 1.00 0.20
ˠTrend test performed without the missing data.
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Table 4 Univariable logistic regression describing the disagreement by subgroups between the official underlying cause of death and the revised underlying
cause of death for women diagnosed with breast cancer in Geneva between 1970 and 2009
All data Between 0 and 4 yearsof follow-up
Between 5 and 9 years of
follow-up
Between 10 and 14 years
of follow-up
N % OR 95% CI N % OR 95% CI N % OR 95% CI N % OR 95% CI
Age (continuous) 5,065 100.0 1.03 [1.02;1.03] 2,497 100.0 1.02 [1.02;1.03] 1,275 100.0 1.02 [1.01;1.04] 626 100.0 1.03 [1.00;1.06]
Age at diagnosis
60-69 1,055 20.8 1 442 17.7 1 239 18.7 1 146 23.3 1
0-49 749 14.8 0.54 [0.37;0.81] 317 12.7 0.63 [0.37;1.07] 210 16.5 0.44 [0.17;1.15] 94 15.0 0.25 [0.71;0.88]
50-59 831 16.4 0.64 [0.45;0.92] 380 15.2 0.62 [0.37;1.03] 210 16.5 1.07 [0.50;2.27] 87 13.9 0.37 [0.12;1.12]
70-79 1,317 26.0 1.10 [0.83;1.46] 600 24.0 1.26 [0.85;1.86] 339 26.6 1.40 [0.73;2.67] 237 37.9 0.66 [0.33;1.32]
80+ 1,113 22.0 1.54 [1.17;2.04] 758 30.1 1.48 [1.02;2.14] 277 21.7 1.48 [0.76;2.88] 62 9.9 1.12 [0.46;2.76]
Years (continuous) 0.99 [0.98;1.00] 0.99 [0.98;1.00] 0.97 [0.95;1.00] 0.94 [0.91;0.97]
Calendar period
70-79 1,576 31.1 1 695 27.8 1 354 27.8 1 198 31.6
N/A
80-89 1,552 30.6 1.00 [0.79;1.27] 686 27.5 1.31 [0.95;1.80] 387 30.5 0.84 [0.50;1.43] 206 32.9
90-99 1,302 25.7 0.69 [0.53;0.91] 654 26.2 0.80 [0.56;1.14] 366 28.7 0.63 [0.36;1.13] 217 34.7
00-09 635 12.5 0.81 [0.58;1.13] 462 18.5 0.82 [0.56;1.22] 168 13.2 0.52 [0.23;1.16] 5 0.8
Social Class
High 597 11.8 1 281 11.3 1 144 11.3 1 77 12.3 1
Medium 2,171 42.9 0.77 [0.56;1.06] 1,034 41.4 0.87 [0.56;1.33] 553 43.3 0.80 [0.38;1.66] 290 46.3 0.56 [0.24;1.28]
Low 1,484 29.3 1.04 [0.75;1.44] 735 29.4 1.24 [0.80;1.92] 363 28.5 1.30 [0.62;2.71] 177 28.3 0.55 [0.22;1.36]
Unknown 813 16.1 1.11 [0.78;1.59] 447 17.9 1.13 [0.70;1.81] 215 16.9 1.08 [0.47;2.45] 82 13.1 1.05 [0.40;2.74]
Stage
Stage I 1,014 20.0 1 280 11.2 1 305 23.9 1 198 31.6 1
Stage II 2,044 40.4 1.24 [0.93;1.66] 901 36.1 1.06 [0.68;1.64] 564 44.2 0.92 [0.53;1.61] 286 46.7 1.24 [0.61;2.52]
Stage III 807 15.9 1.48 [1.06;2.07] 538 21.6 1.03 [0.64;1.64] 175 13.7 1.36 [0.69;2.68] 58 9.3 1.95 [0.74;5.15]
Stage IV 490 9.7 1.25 [0.84;1.85] 427 17.1 0.87 [0.52;1.44] 50 3.9 0.28 [0.04;2.10] 8 1.3 4.74 [0.87;25.87]
Unknown 710 14.0 1.59 [1.13;2.23] 351 14.1 1.51 [0.93;2.44] 181 14.2 1.22 [0.61;2.44] 76 12.1 1.22 [0.45;3.33]
Treatment
Surgery only 1,252 24.7 1 436 17.5 1 323 25.3 1 216 34.5 1
Surg + adj. 2,693 53.2 0.78 [0.61;1.01] 1,186 47.5 0.58 [0.40;0.84] 766 60.1 0.85 [0.51;1.41] 367 58.6 0.99 [0.52;1.89]
No treatment 421 8.3 2.50 [1.82;3.43] 317 12.7 1.84 [1.23;2.75] 69 5.4 1.41 [0.58;3.41] 23 3.7 4.41 [1.53;12.75]
Hormones 448 8.9 1.76 [1.26;2.46] 345 13.8 1.34 [0.88;2.03] 88 6.9 1.25 [0.54;2.88] 14 2.2 0.96 [0.12;7.83]
Others 251 5.0 1.34 [0.86;2.10] 213 8.5 1.00 [0.60;1.67] 29 2.3 0.44 [0.06;3.41] 6 1.0 2.50 [0.28;22.71]
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Table 4 Univariable logistic regression describing the disagreement by subgroups between the official underlying cause of death and the revised underlying
cause of death for women diagnosed with breast cancer in Geneva between 1970 and 2009 (Continued)
Period of death
continuous 0.97 [0.96;0.98] 0.98 [0.97;1.00] 0.98 [0.96;1.00] 0.94 [0.90;0.97]
70-79 630 12.4 1 548 21.9 1 82 6.4 1
N/A
80-89 1,196 23.6 1.01 [0.75;1.36] 658 26.4 1.18 [0.84;1.66] 362 28.4 0.60 [0.28;1.30] 149 23.8
90-99 1,483 29.3 0.69 [0.51;0.93] 694 27.8 0.86 [0.6;1.23] 377 29.6 0.51 [0.24;1.11] 211 33.7
00-10 1,756 34.7 0.45 [0.33;0.61] 597 23.9 0.65 [0.44;0.96] 454 35.6 0.44 [0.20;0.95] 266 42.5
Age at death
continuous 1.02 [1.01;1.02] 1.02 [1.01;1.03] 1.02 [1.01;1.04] 1.03 [1.00;1.05]
60-69 813 16.1 1 427 17.1 1 222 17.4 1 87 13.9 1
0-49 353 7.0 0.65 [0.39;1.08] 248 9.9 0.66 [0.37;1.18] 94 7.4 0.30 [0.67;1.34] 8 1.3 2.34 [0.24;22.94]
50-59 593 11.7 0.49 [0.31;0.79] 350 14.0 0.51 [0.29;0.90] 160 12.6 0.54 [0.20;1.42] 64 10.2 0.26 [0.30;2.28]
70-79 1,105 21.8 1.13 [0.82;1.56] 580 23.2 1.25 [0.83;1.86] 270 21.2 1.10 [0.55;2.21] 130 20.8 1.22 [0.39;3.77]
80+ 2,201 43.5 1.23 [0.93;1.63] 892 35.7 1.46 [1.01;2.10] 529 41.5 1.31 [0.72;2.41] 337 53.8 1.90 [0.72;5.01]
Place of death
Public hospital 2,845 56.2 1 1,573 63.0 1 677 53.1 1 315 50.3
N/A
Retirement home 1,291 25.5 0.74 [0.58;0.93] 570 22.8 0.87 [0.64;1.17] 328 25.7 0.71 [0.41;1.22] 172 27.5
Private hospital 150 3.0 0.59 [0.31;1.14] 55 2.2 0.54 [0.19;1.51] 47 3.7 1.37 [0.52;3.62] 24 3.8
Home 374 7.4 0.37 [0.22;0.62] 143 5.7 0.20 [0.07;0.54] 113 8.9 0.76 [0.34;1.72] 54 8.3
Others 263 5.2 0.13 [0.05;0.35] 122 4.9 0.11 [0.03;0.47] 70 5.5 0.17 [0.02;1.23] 38 6.1
Missing 142 2.8 0.30 [0.12;0.75] 34 1.4 0.21 [0.03;1.53] 40 3.1 0.94 [0.28;3.13] 25 4.0
Sector of care
Private 2,028 40.0 1 870 34.8 1 550 43.1 1 286 45.7 1
Public 3,037 60.0 1.47 [1.20;1.81] 1,627 65.2 1.61 [1.21;2.14] 725 56.9 1.02 [0.66;1.58] 340 54.3 1.60 [0.88;2.91]
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the reviewed cause of death vs. 32.7%, 95% CI [25.9;
39.6] when using the variable based only on death certif-
icates. In the same way, the survival at 10-year was 5%
higher for 80+ when using the reviewed cause of death
(47.7%, 95% CI [43.1; 52.1] vs. 42.7%, 95% CI [38.4;
47.0]). Among patients with metastatic tumours, the dif-
ference was in the opposite direction: the estimation of
10-year survival was 1.5% higher when using the cause
of death based on death certificates only, 14.7%, 95% CI
[11.2; 18.7] vs.13.2%, 95% CI [10.0; 16.9] for the reviewed
cause of death.
Discussion and conclusion
Survival statistics derived from routinely collected
population-based cancer registry data are key means of
reporting progress against cancer. In the Geneva Cancer
Registry, in addition to the official underlying cause of
death derived from the death certificate, registrars use
all the available information in order to establish, where
relevant, a revised underlying cause of death which
allows evaluation of the accuracy of death certification.
This study describes both processes of recording the
cause of death and shows their impact upon estimated
survival rates from breast cancer.
The overall concordance between the official and the
revised underlying cause of death was high. Differences
were only present for 8.8% of the deceased patients
representing 4.2% of the entire cohort. This is consistent
with the study conducted by Goldoni et al. [11] in 2009
who reported 4.3% misclassification among their cohort.
The official underlying cause of death was revised to
breast cancer in 191 women (3.8% of those who have
died) according to the cancer registry registrars; the
underlying cause of death of these women had mainly
been coded to other tumours. This could be explained
by the presence of metastases that may have misled the
certifying doctor about the location of the primary can-
cer and leads to differences in cause-specific survival es-
timation among metastatic patients (Figure 2).
On the other hand, most of the 254 women (5.0% of
the patients who have died), coded as breast cancer
deaths on the death certificates and considered as deaths
from other causes from the registry, have been attributed
to heart disease. Most of these women were elderly pa-
tients diagnosed during 1970–89. At that time the guid-
ance for death certification among cancer registries was
not to emphasize the cancer as a cause of death [16].
This might explain a tendency to recode the cause of
death from cancer to heart diseases among elderly.
Our results based on Kappa statistic and on logistic re-
gression showed that disagreement was greater among
elderly women, patients with advanced disease and pa-
tients receiving palliative treatment. This suggests that
less attention is given by doctors certifying death to the
underlying cause of death for patients who are more
likely to die. Concordance is also lower within the first
five years after diagnosis, suggesting that more accurate
information is available to the registrars assessing the
true underlying cause of death during a shorter period
of follow-up.
We also observed increasing concordance in succes-
sive calendar periods of death. Since this variable closely
represents the year in which the review took place, sev-
eral explanations may apply. First, the Geneva Cancer
Registry may have less information in more recent times.
This seems unlikely since more linkages have been set
up over time with the health system in the canton,
allowing a greater exchange of data. More likely, the ac-
curacy of death certificates has improved over time
which has led to more confidence in the official coding
supplied on death certificates.
It is legitimate to ask why the reliability of cause of
death reported on the death certificates may be ques-
tioned at all. It can be argued that the general practi-
tioner responsible for the patient is the person most
likely to be aware of the underlying cause of death inso-
far as they are aware of all the clinical information and
also often know the patients personally. However, this ad-
vantage is not always capitalised on. Physicians are more
likely to misclassify the cause of death than a trained
registrar [4,10,17-19]. The general practitioner is not al-
ways concerned about the epidemiological information
they are providing, and may not be aware of the inter-
national rules of WHO about the coding of the cause of
death. Moreover, the general practitioner often receives
the results of the autopsy after the death certificate has
been issued and therefore does not take into account the
report when certifying the death. The registrars of the
Using the official cause of death (1)
Using the revised cause of death (2)
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Figure 1 Up-to-20-year cancer-specific survival using 1) the
cause of death based on death certificate only and 2) cause of
death reviewed by registrars and the absolute difference be-
tween them: female breast cancer patients diagnosed between
1970 and 2009.
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Geneva Cancer Registry, on the other hand, are able to ac-
cess all pathological and histological information and/or
the clinical information for most cases and review the
cause of death only in the light of the autopsy reports. In
addition, the registrars are more experienced with epi-
demiological data and its coding.
James [20] showed that coding the cause of death
using death certificates only, in isolation from all other
available information, led to biased interpretations of the
cause of death. Our study tends to legitimate the process
of verification that is performed in the Geneva Cancer
Registry and induces that the resulting estimation of sur-
vival is more accurate.
Both methods aim to assign as best as possible the cause
of death and none of them can be considered as the gold
standard. We nevertheless consider the revised cause of
death as more accurate insofar as additional information
is available to experienced registrars but not necessarily to
the practitioner completing the death certificate.
Overall, the revised underlying cause of death did not
have a major impact on the cause-specific survival up to
20 years. However, important differences appeared in sev-
eral subgroups suggesting that using the official under-
lying cause of death could lead to biased estimation of
cause-specific survival in some populations.
The main limitation of this study relates to the propor-
tion of women who have died for whom information
other than the death certificate was available. The more
information available, the more likely it is that we will be
able to find discordance. High concordance reflects ei-
ther lack of additional information available to correct
the official cause of death, or that the death certificates
define the cause of death fairly well. However, among
our cohort of 5,062 deceased patients, a high percentage
was monitored and/or passed away in the public sector
of care, where access to information about cause of death
is more readily available. We therefore assume that infor-
mation enabling review of the underlying cause of death
was available for the great majority of women who had
died and that the overall high concordance between offi-
cial and revised underlying cause of death is real.
Moreover, the number of deaths in the cohort influ-
ences the discordance. The more deaths, the more likely
it is to find differences between the two causes-of-death
and then the concordance. This state is confirmed in our
study with a higher discordance among elderly. Breast
cancer is not the more lethal cancer and our results can
certainly not be generalised to other tumour localisations.
The Geneva Cancer registry data represent a unique
opportunity to review the accuracy of the cause of death
recorded on a death certificate by comparing it to all the
available information in the health system. We observed
that the overall concordance with the cause of death
found on the death certificates is fairly high. More
particularly, the impact on estimates of cause-specific
survival is very small overall, although analyses in sub-
groups show larger differences, suggesting that mis-
classification of the underlying cause of death could lead
to biased estimation of differences or trends in cause-
specific survival.
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